Improving outcomes in patients with advanced renal cell carcinoma

References

• Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol.23(4), 832–841 (2005).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med.335(12), 865–875 (1996).
   PubMed Web of Science ®Google Scholar
• Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin. Oncol.22(1), 42–60 (1995).
   PubMed Web of Science ®Google Scholar
• Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer101(7), 1545–1551 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol.163(2), 408–417 (2000).
   PubMed Web of Science ®Google Scholar
• David KA, Milowsky MI, Nanus DM. Chemotherapy for non-clear-cell renal cell carcinoma. Clin. Genitourin. Cancer.4(4), 263–268 (2006).
   Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol.13(3), 688–696 (1995).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol.166(5), 1611–1623 (2001).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler W et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17(8), 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol.166(1), 63–67 (2001).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20(1), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol.168(6), 2395–2400 (2002).
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol.20(23), 4559–4566 (2002).
   PubMed Web of Science ®Google Scholar
• Karakiewicz PI, Briganti A, Chun FK et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J. Clin. Oncol.25(11), 1316–1322 (2007).
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol.21(16), 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol.23(1), 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am.6(Suppl. 1), S55–S57 (2000).
   PubMed Web of Science ®Google Scholar
• Pyrhönen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon α-2α plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol.17(9), 2859–2867 (1999).
   PubMed Web of Science ®Google Scholar
• Medical Research Council Renal Cancer Collaborators. interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet353(9146), 14–17 (1999).
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345(23), 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon α-2a, interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer110(11), 2468–2477 (2007).
   PubMed Web of Science ®Google Scholar
• Négrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann. Oncol.13(9), 1460–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer92(10), 1855–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24(16), 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol.25(Suppl. 18), (Abstract 5023) (2007).
   PubMedGoogle Scholar
• Gollob JA, Rathmell WK, Richmond TM et al. Phase II trial of sorafenib plus interferon α-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol.25(22), 3288–3295 (2007).
   PubMed Web of Science ®Google Scholar
• Ryan CW, Goldman BH, Lara PN Jr et al. Sorafenib with interferon α-2b as first-line treatment of advanced renal carcinoma: a Phase II study of the Southwest Oncology Group. J. Clin. Oncol.25(22), 3296–3301 (2007).
   PubMed Web of Science ®Google Scholar
• Szczylik C, Demkow T, Staehler M et al. Randomized Phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. Proc. Am. Soc. Clin. Oncol.25(S18), (Abstract 5025) (2007).
   Google Scholar
• Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res.9(1), 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood101(9), 3597–3605 (2003).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24(1), 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295(21), 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ. Sunitinib versus interferon-α (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J. Clin. Oncol.24(Suppl. 18), (Abstract 5024) (2007).
   Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Torisel™ package insert. Wyeth Pharmaceuticals, Inc., PA, USA (2007).
   Google Scholar
• Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell103(2), 253–262 (2000).
   PubMed Web of Science ®Google Scholar
• Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell Biol.24(1), 200–216 (2004).
   PubMed Web of Science ®Google Scholar
• DelBufalo D, Ciuffreda L, Trisciuoglio D et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res.66(11), 5549–5554 (2006).
   Google Scholar
• Mamane Y, Petroulakis E, Lebacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene25(48), 6416–6422 (2006).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22(5), 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Dutcher J, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age and prognostic-risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha. J. Clin. Oncol.25(Suppl.18), (Abstract 5033) (2007).
   Google Scholar
• Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol.26(1), 127–131 (2008).
   PubMed Web of Science ®Google Scholar
• Mallick RS, Parasuraman S, Hudes G et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-α (IFN) or the combination of IFN + TEMSR [poster]. Presented at: Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Patnaik A, Ricart A, Cooper J et al. A Phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J. Clin. Oncol.25(Suppl. 18), (Abstract 3512) (2007).
   PubMedGoogle Scholar
• Merchan JR, Liu G, Fitch T et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J. Clin. Oncol.25(18S), (Abstract 5034) (2007).
   Google Scholar
• Robins HI, Wen PY, Chang SM et al. Phase I study or erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04–02). J. Clin. Oncol.25(18S), Abstract 2057 (2007).
   Google Scholar
• Amato RJ, Misellati A, Khan M, Chiang S. A Phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) [abstract]. J. Clin. Oncol.18(24 Suppl.), (Abstract 4530) (2006).
   Google Scholar
• Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R. A Phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). J. Clin. Oncol.25(18S), (Abstract 5107) (2007).
   Google Scholar
• Amato RJ, Harris P, Dalton M et al. A Phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell carccinoma (mRCC) [abstract]. J. Clin. Oncol.25(Suppl. 18), (Abstract 5026) (2007).
   Google Scholar